Wells Fargo’s Amneal Pharmaceuticals AMRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.31M | Buy |
422,395
+317,277
| +302% | +$4.35M | ﹤0.01% | 2484 |
|
|
2026
Q1 | $1.31M | Sell |
105,118
-67,558
| -39% | -$907K | ﹤0.01% | 3577 |
|
|
2025
Q4 | $2.18M | Buy |
172,676
+76,761
| +80% | +$878K | ﹤0.01% | 3363 |
|
|
2025
Q3 | $960K | Buy |
95,915
+15,194
| +19% | +$136K | ﹤0.01% | 3850 |
|
|
2025
Q2 | $653K | Buy |
80,721
+1,002
| +1% | +$7.55K | ﹤0.01% | 3962 |
|
|
2025
Q1 | $668K | Buy |
79,719
+1,746
| +2% | +$14.6K | ﹤0.01% | 3891 |
|
|
2024
Q4 | $618K | Sell |
77,973
-99,862
| -56% | -$838K | ﹤0.01% | 4040 |
|
|
2024
Q3 | $1.48M | Buy |
177,835
+118,490
| +200% | +$927K | ﹤0.01% | 3279 |
|
|
2024
Q2 | $377K | Buy |
59,345
+10,867
| +22% | +$69K | ﹤0.01% | 4090 |
|
|
2024
Q1 | $294K | Buy |
48,478
+10,362
| +27% | +$58.4K | ﹤0.01% | 4236 |
|
|
2023
Q4 | $231K | Buy |
38,116
+6,872
| +22% | +$30.6K | ﹤0.01% | 4379 |
|
|
2023
Q3 | $132K | Sell |
31,244
-25,262
| -45% | -$94.2K | ﹤0.01% | 4614 |
|
|
2023
Q2 | $175K | Buy |
56,506
+34,416
| +156% | +$73.3K | ﹤0.01% | 4667 |
|
|
2023
Q1 | $30.7K | Buy |
22,090
+20,879
| +1,724% | +$41.6K | ﹤0.01% | 5437 |
|
|
2022
Q4 | $2.41K | Sell |
1,211
-12,651
| -91% | -$28.4K | ﹤0.01% | 5965 |
|
|
2022
Q3 | $28K | Sell |
13,862
-1,122
| -7% | -$3.14K | ﹤0.01% | 5220 |
|
|
2022
Q2 | $48K | Sell |
14,984
-221,818
| -94% | -$804K | ﹤0.01% | 5036 |
|
|
2022
Q1 | $988K | Sell |
236,802
-151,101
| -39% | -$669K | ﹤0.01% | 3900 |
|
|
2021
Q4 | $1.86M | Sell |
387,903
-366,788
| -49% | -$1.83M | ﹤0.01% | 3577 |
|
|
2021
Q3 | $4.03M | Sell |
754,691
-119,913
| -14% | -$604K | ﹤0.01% | 3035 |
|
|
2021
Q2 | $4.48M | Buy |
874,604
+40,822
| +5% | +$232K | ﹤0.01% | 2967 |
|
|
2021
Q1 | $5.61M | Buy |
833,782
+497,351
| +148% | +$2.76M | ﹤0.01% | 2738 |
|
|
2020
Q4 | $1.54M | Sell |
336,431
-35,692
| -10% | -$158K | ﹤0.01% | 3681 |
|
|
2020
Q3 | $1.45M | Buy |
372,123
+63,124
| +20% | +$270K | ﹤0.01% | 3577 |
|
|
2020
Q2 | $1.47M | Buy |
308,999
+94,673
| +44% | +$390K | ﹤0.01% | 3514 |
|
|
2020
Q1 | $746K | Sell |
214,326
-386,559
| -64% | -$1.64M | ﹤0.01% | 3736 |
|
|
2019
Q4 | $2.9M | Sell |
600,885
-321,020
| -35% | -$1.12M | ﹤0.01% | 3034 |
|
|
2019
Q3 | $2.67M | Buy |
921,905
+734,549
| +392% | +$2.56M | ﹤0.01% | 3078 |
|
|
2019
Q2 | $1.34M | Sell |
187,356
-183,313
| -49% | -$1.87M | ﹤0.01% | 3665 |
|
|
2019
Q1 | $5.25M | Buy |
370,669
+44,154
| +14% | +$584K | ﹤0.01% | 2504 |
|
|
2018
Q4 | $4.42M | Buy |
326,515
+26,167
| +9% | +$472K | ﹤0.01% | 2550 |
|
|
2018
Q3 | $6.67M | Buy |
300,348
+13,037
| +5% | +$274K | ﹤0.01% | 2409 |
|
|
2018
Q2 | $4.71M | Buy |
+287,311
| New | +$5.04M | ﹤0.01% | 2743 |
|
Other funds holding AMRX
TGA
RCMNY
Wells Fargo's AMRX Position: Q2 2026 in Review
Wells Fargo increased its Amneal Pharmaceuticals (AMRX) stake by 302% in Q2 2026, buying an estimated $4.35M and bringing the position to 422,395 shares worth $7.31M. The position accounts for ﹤0.01% of the portfolio, ranked #2484.
Wells Fargo first reported a position in AMRX in Q2 2018 and has held it in 33 quarters since. 306 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.
- Wells Fargo held 422,395 shares of Amneal Pharmaceuticals worth $7.31M as of Q2 2026.
- Wells Fargo bought 317,277 Amneal Pharmaceuticals shares in Q2 2026, an estimated $4.35M.
- Amneal Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #2484 holding.
- Wells Fargo first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 33 quarters since.
- 306 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.
Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.